公开(公告)号：US5264217A

公开(公告)日：1993-11-23

申请号：US959472

申请日：1992-10-09

Applicant: David F. Horrobin

Inventor： David F. Horrobin

IPC: A61K31/20

CPC classification number: A61K31/20 ,  Y10S514/922

Abstract: Methods for increasing the total fat and therefore energy content of mammalian and particularly human milk, the essential fatty acid content of that milk and the flow of that milk during lactation, or for preventing or reducing the normal decrease in milk fat content that occurs during prolonged lactation, by administering gamma linolenic acid, dihomo-gamma-linolenic acid or their mixture, alone or a physiologically acceptable diluent or carrier, in a form administrable to the lactating female.

Abstract translation: 增加哺乳动物和特别是人乳的总脂肪，因此能量含量的方法，该乳的必需脂肪酸含量和哺乳期间该奶的流动，或用于预防或减少在长时间内发生的乳脂含量的正常降低 通过以可施用于哺乳期雌性的形式单独或单独或生理上可接受的稀释剂或载体施用γ-亚麻酸，二亚非 - γ-亚麻酸或其混合物。

公开(公告)号：US5262174A

公开(公告)日：1993-11-16

申请号：US732492

申请日：1991-07-18

Applicant: David F. Horrobin

Inventor： David F. Horrobin

IPC: A61K31/19 ,  A61K31/505 ,  A61K33/14 ,  A61K38/21 ,  A61K31/70

CPC classification number: A61K31/70 ,  A61K31/19 ,  A61K31/505 ,  A61K33/14 ,  A61K38/21

Abstract: The treatment of viral infections with a lithium salt and one of cytarabine or idoxuridine.

Abstract translation: 用盐酸盐治疗病毒感染，阿糖尿病或阿托脲治疗。

公开(公告)号：US5252333A

公开(公告)日：1993-10-12

申请号：US329881

申请日：1989-03-28

Applicant: David F. Horrobin

Inventor： David F. Horrobin

IPC: A01N37/06 ,  A23L1/304 ,  A61K8/19 ,  A61K8/36 ,  A61K8/67 ,  A61K9/28 ,  A61K31/20 ,  A61L15/44 ,  A61Q5/02 ,  A61Q19/00 ,  A61F13/00 ,  A61K9/00

CPC classification number: A61K8/67 ,  A01N37/06 ,  A23L33/16 ,  A61K31/20 ,  A61K8/19 ,  A61K8/361 ,  A61Q19/00 ,  A61Q5/02 ,  Y10S514/81 ,  Y10S514/821 ,  Y10S514/824 ,  Y10S514/825 ,  Y10S514/866 ,  Y10S514/885 ,  Y10S514/886 ,  Y10S514/905 ,  Y10S514/931 ,  Y10S514/934 ,  Y10S514/943

Abstract: The invention provides pharmaceutical and disinfectant compositions containing lithium salts of C.sub.18-22 polyunsaturated fatty acids. The compositions may be used in the treatment of conditions responsive to lithium and/or polyunsaturated fatty acid therapy, in parenteral alimentation or food supplements or in surface disinfection to combat transmission of viral diseases.

Abstract translation: 本发明提供含有C18-22多不饱和脂肪酸的锂盐的药物和消毒剂组合物。 组合物可用于治疗对锂和/或多不饱和脂肪酸治疗，肠胃外营养或食物补充剂或表面消毒作用以对抗病毒性疾病传播的病症。

公开(公告)号：US5116871A

公开(公告)日：1992-05-26

申请号：US397789

申请日：1989-08-24

Applicant: David F. Horrobin ,  John C. M. Stewart

Inventor： David F. Horrobin ,  John C. M. Stewart

IPC: A61K31/20 ,  A61K38/21 ,  A61P9/00 ,  A61P25/00 ,  A61P25/04 ,  A61P29/00 ,  A61P31/12 ,  A61P43/00

CPC classification number: A61K31/20 ,  A61K38/21

Abstract: The use of one or more of the 6-desaturated or higher EFAs of each of the n-6 and n-3 series for the manufacture of a medicament for use in the treatment of post-viral fatigue syndrome (otherwise known as myalgic encephalomyelitis (ME)).

公开(公告)号：US5116624A

公开(公告)日：1992-05-26

申请号：US638998

申请日：1991-01-09

Applicant: David F. Horrobin ,  Frank Corrigan

Inventor： David F. Horrobin ,  Frank Corrigan

IPC: A61K31/20 ,  A61K31/202 ,  A61K31/315 ,  A61K33/04 ,  A61K33/30 ,  A61K35/60 ,  A61K36/00 ,  A61K36/18 ,  A61P25/24 ,  A61P25/26 ,  A61P25/28

CPC classification number: A61K33/04 ,  A61K31/315 ,  A61K33/30 ,  A61K35/60 ,  A61K36/06

Abstract: A pharmaceutical composition of GLA or DGLA and bioavailable selenium, optionally also with an 18:4 or higher n-3 EFA and/or bioavailable zinc.

公开(公告)号：US4886670A

公开(公告)日：1989-12-12

申请号：US159128

申请日：1988-02-23

Applicant: David F. Horrobin

Inventor： David F. Horrobin

IPC: A61K31/19 ,  A61K31/505 ,  A61K33/14 ,  A61K38/21

CPC classification number: A61K31/70 ,  A61K31/19 ,  A61K31/505 ,  A61K33/14 ,  A61K38/21

Abstract: The anti-viral effectiveness of conventional anti-viral agents such as acylovir, idoxuridine, vidarabine etc. is enhanced by formulation or administration with a physiologically acceptable lithium salt.

Abstract translation: 常规抗病毒剂如acylovir，idoxuridine，阿糖腺苷等的抗病毒效能通过与生理上可接受的锂盐的配制或施用来增强。

公开(公告)号：USRE31836E

公开(公告)日：1985-02-19

申请号：US581671

申请日：1984-02-16

Applicant: David F. Horrobin

Inventor： David F. Horrobin

IPC: A61K31/20 ,  A61K31/23 ,  A61K31/375 ,  A61K31/43 ,  A61K31/485 ,  A61K33/30 ,  A61K45/06

CPC classification number: A61K33/30 ,  A61K31/20 ,  A61K31/23 ,  A61K31/375 ,  A61K31/43 ,  A61K31/485 ,  A61K45/06

Abstract: Composition and use of .gamma.-linolenic acid and related materails with ascorbic acid, or ethyl alcohol, or an opiate antagonist such as naloxone, nalorphine or levallorphan, for treating alcoholism or moderating the effects of taking alcohol.

公开(公告)号：US4444755A

公开(公告)日：1984-04-24

申请号：US272081

申请日：1981-06-10

Applicant: David F. Horrobin

Inventor： David F. Horrobin

IPC: A61K31/43 ,  A61K31/545 ,  A61K33/30 ,  A61K31/20 ,  A61K31/315 ,  A61K31/54

CPC classification number: A61K33/30 ,  A61K31/43 ,  A61K31/545

Abstract: Use of .gamma.-linolenic acid and related materials alone or with zinc or .beta.-lactam antibiotics to treat skin disorders.

Abstract translation: 单独或与锌或β-内酰胺抗生素一起使用γ-亚麻酸及相关物质治疗皮肤病。

公开(公告)号：US4309415A

公开(公告)日：1982-01-05

申请号：US29058

申请日：1979-04-11

Applicant: David F. Horrobin

Inventor： David F. Horrobin

IPC: A23L1/29 ,  A23L1/30 ,  A61K31/20 ,  A61K31/202 ,  A61K31/23 ,  A61K31/34 ,  A61K31/40 ,  A61K31/425 ,  A61K31/43 ,  A61K31/475 ,  A61K31/557 ,  A61K33/30 ,  A61K38/00 ,  A61K38/21 ,  A61K45/06 ,  A61P13/02 ,  A61P15/00 ,  A61P29/00 ,  A61P35/00 ,  A61P37/00 ,  A61P43/00 ,  A61K45/02 ,  A61K31/54

CPC classification number: A61K38/21 ,  A61K31/20 ,  A61K31/23 ,  A61K31/34 ,  A61K31/40 ,  A61K31/425 ,  A61K31/43 ,  A61K31/475 ,  A61K31/557 ,  A61K33/30 ,  A61K45/06

Abstract: Compositions and use of .gamma.-linolenic acid and related materials with (i) zinc, .beta.-lactam antibiotics or other materials enhancing physiological 1-series PG synthesis and/or (ii) colchicine, Vinca alkaloids or other materials enhancing physiological synthesis of thromboxane A2, for treatment of inflammatory disorders.

Abstract translation: γ-亚麻酸及相关材料与（i）锌，β-内酰胺抗生素或其他增强生理性1系PG合成的物质和/或（ii）秋水仙碱，长春花生物碱或其他增强凝血恶烷A2生理合成的物质的组合和用途 ，用于治疗炎症性疾病。

公开(公告)号：US4287202A

公开(公告)日：1981-09-01

申请号：US38938

申请日：1979-05-14

Applicant: David F. Horrobin

Inventor： David F. Horrobin

IPC: A61K31/405 ,  A61K31/47

CPC classification number: A61K31/405 ,  A61K31/47

Abstract: A method for the treatment or prophylaxis of angina pectoris or myocardial infarction which consists of administering indomethacin or chloroquine. It has been found that angina pectoris and myocardial infarction may be susceptible to treatment by administration of substances which will inhibit the synthesis or action of prostaglandins, which it is believed to be the effect of administering indomethacin or chloroquine.

Abstract translation: 治疗或预防心绞痛或心肌梗死的方法，其包括给予吲哚美辛或氯喹。 已经发现，心绞痛和心肌梗塞可能通过施用将抑制前列腺素合成或作用的物质来治疗，这被认为是施用吲哚美辛或氯喹的作用。